INTICA Biomedical, Inc.

Website http://www.inticabio.com

Founded 2011

Employees 3

Overview

INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.

Management Team

Founder

Vicky Herrera

Professor of Medicine Boston University School of Medicine, Pediatric Cardiology, Molecular Medicine, co-discovery DEspR target, development DEspR-targeted therapy & Diagnostics

President, CEO & Founder

Christine Bunt

Christine Bunt is Founder and CEO of INTICA Biomedical, a new life science start-up company, currently still in stealth mode. Prior to INTICA, Christine founded TARIS Biomedical together with Prof. Michael Cima and Prof. Robert Langer from MIT, Cambridge, MA. Previously, Christine was with Merck & Co. for seven years in Whitehouse Station, NJ, where she was leading worldwide commercialization for VIOXX, MAXALT and Cardiovascular Hospital Products

Founder

Nelson Ruiz Opazo

Professor Of Medicine Boston University, Molecular and Cell Biology, co-inventor transgenic rat atherosclerosis model, licensed to Pharmacia through NoMI, co-discovery DEspR target, development DEspR-targeted therapy & Diagnostics

Vice President of Development

Christopher Horvath

D.V.M, Lead preclinical development of 5 companies, lead IND & toxicology studies for Millenium Mabs; 6+ MAB/Protein INDs. Lead Development Taligen, Exit preclinical: $ 110 MM

Advisory Board Member/ Dana Faber

Patrick Wen

Dr. Wen is Director of Neuro-Oncology at the Dana Faber Cancer Institure in Boston, MA. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer. Dr. Wen is a Professor of Neurology, Harvard Medical School. Dr. Wen currently oversees more than 30 clinical trials in the fields of brain cancer/glioblastoma.

Advisory Board Member & Consultant

William Li

Dr. Li is President, Medical Director, and Co-founder of the Angiogenesis Foundation. Dr Li trained in the lab of Dr. Judah Folkman and has been actively engaged in angiogenesis research and clinical development for 22 years

Chairman Scientific Advisory Board

Dennis Ausiello

Dr. Ausiello is the Jackson Professor of Clinical Medicine at Harvard Medical School, Chief of Medicine at Massachusetts General Hospital (MGH), and Chief Scientific Officer of Partners Healthcare. Dr. Ausiello serves as the Chairman of the Scientific Advisory Board for INTICA Biomedical.

Advisory Board Member / ASCO President

George Sledge

Dr. Sledge currently serves as the Ballve-Lantero Professor of Oncology and Professor of Pathology and Laboratory Medicine at the Indiana University Melvin and Bren Simon Cancer Center. Dr. Sledge is also an active member of the American Association for Cancer Research (AACR) and serves as Chairman of the Breast Cancer Committee, Hoosier Oncology Group.

Advisory Board Member/ MIT

Sangeeta Bhatia

Dr. Bhatia is Professor of Health Sciences and Technology and Professor of Electrical Engineering and Computer Science, MIT, Cambridge, Ma. Dr. Bhatia's research in the Laboratory for Multiscale Regenerative Technologies is focused on the applications of micro- and nanotechnology to tissue repair and regeneration. Her research includes a multidisciplinary effort to develop nanomaterials as tools for biological studies and as multifunctional agent